BioSpace News Archive

Under the terms of the merger, existing Vical stockholders will own 40% of the combined company and Brickell shareholders will own 60%.

The experimental drug enfortumab vedotin, developed by Astellas and Seattle Genetics, demonstrated a 44% objective response rate in patients.

Novotech, the Asia-Pacific CRO, has again won the prestigious Asia-Pacific CRO of the year awarded by leading analyst firm Frost & Sullivan.

Nearly half the amplitude typically used in standard electroconvulsive therapy (ECT) seems to be effective at treating suicidal thoughts, investigators report.

PromarkerD world’s leading diagnostic test for diabetic kidney disease says Frost & Sullivan industry report ‘Biomarkers Enabling Diabetes and Obesity Management’

WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary of Mateon Therapeutics Inc., to provide OT-101 to patients who cannot take part in research trials of the investigational product.

Arcutis, Inc. announced that it has enrolled the first patient in a Phase 2a clinical trial evaluating ARQ-151 as a potential treatment for atopic dermatitis (AD).

Frontage Holdings Corporation, the parent company of Frontage Laboratories, Inc., a fast-growing contract research organization, specializing in R&D product development services, with operations in both the United States and China, announced on May 30th that the Company’s Shares have initiated trading on the Main Board of The Stock Exchange of Hong Kong.

Overall survival rates in the intent-to-treat population at 42 months for the Kisquali combination group was 70.2% compared to 46.0% for hormone therapy alone.

Phase one of the construction project will start in August. Once completed, its annual capacity will be more than $1 billion of plasmid DNA, RNA, gene editing enzymes and other biologics.